Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Conditions:   Ovarian Cancer;   Ovarian Neoplasms;   Ovarian Carcinosarcoma;   Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Fallopian Tube Cancer;   Fallopian Tube Neoplasms;   Primary Peritoneal Carcinoma;   Primary Per itoneal Serous Adenocarcinoma Interventions:   Drug: Paclitaxel;   Drug: TAK228 Sponsors:   Imperial College London;   Takeda Pharmaceuticals International, Inc.;   North Eastern Germany Society of Gynaecologic Oncology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials